Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis-Reference-Cited by-同舟云学术

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

Published:2018-12 Issue:1 Volume:17 Page:
ISSN:1476-511X
Container-title:Lipids in Health and Disease
language:en
Short-container-title:Lipids Health Dis

Author:

Sicras-Mainar A.,Sánchez-Álvarez L.,Navarro-Artieda R.,Darbà J.

Funder

Pfizer S.L.U.

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1186/s12944-018-0918-y.pdf

Reference44 articles.

1. Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160.

2. Salinas Botrán A, Ramos Rincón JM, de Górgolas Hernández-Mora M. Cardiovascular disease: a view from global health perspective. Med Clin (Barc). 2013;141(5):210–6.

3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias: the task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR). Rev Esp Cardiol (Engl Ed). 2017;70(2):72–7.

4. Gómez-Huelgas R, Pérez-Jiménez F, Serrano-Ríos M, González-Santos P, Román P, Camafort M, et al. SEMI working group; Spanish Society of Internal Medicine. Clinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine. Rev Clin Esp (Barc). 2014;214(4):209–15.

5. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. Canadian cardiovascular society guidelines for the Management of Dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–82.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact and implications of national centralized drug procurement in China;International Journal of Clinical Pharmacy;2024-07-11

2. Clinical equivalence of generic and brand-name drugs used in cardiology: what do we know?;Consilium Medicum;2021-12-15

3. Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy;Cardiology and Therapy;2021-09-29

4. Persistencia al tratamiento con metformina de marca vs. genérica en monoterapia para la diabetes tipo 2: estudio retrospectivo de vida real mediante propensity score matching;Medicina de Familia. SEMERGEN;2021-07

5. Metabolic Changes in Hyperlipidemic Rats After The Administration of Xuezhikang;Current Pharmaceutical Analysis;2021-05-05